Request Free Demo
"My patient had a history of post menopausal bleeding and had an abnormal Pap. The Pipelle came back with insufficient tissue. A D&C Hysteroscopy was done in the O.R., but that also came back with insufficient tissue. Lastly, I tried the Tao Brush and got a successful diagnosis off of cytology."
Marlo Carter M.D.
Women’s Wellness Healthcare Associates, Limerick, PA

HPV Testing by cobas®*

Gynecor provides the FDA approved cobas HPV test, a qualitative multiplex assay that provides specific genotyping information for HPV Types 16 and 18, while concurrently detecting the other 12 high-risk HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) in a pooled result.

Screening for certain high-risk HPV strains helps identify women at the highest risk of developing cervical cancer. This can help determine if patients need further testing, immediate treatment, or how often patients need to be tested in the future.

Roche’s landmark ATHENA study is cited as a central study providing the evidence for differential patient management based on HPV 16 and 18 genotyping. This study showed that 1 in 10 women with normal cytology who tested positive for HPV 16 and/or HPV 18 also had high-grade cervical disease that was missed by cytology.

The cobas HPV test can be run from the SurePath or ThinPrep liquid-based Pap test, from endocervical specimens provided in Gynecor’s proprietary NuFix vial, or from cervical tissue collected from cervical biopsy.

*cobas is a trademark of Roche Diagnostics